Clinical trials: Acute ST-elevation Myocardial Infarction
Acute Coronary Syndromes, ST Elevation Myocardial Infarction
Smartphone AI Assistance for Prehospital ECG Interpretation
Prehospital providers interpret 12-lead electrocardiograms (ECGs) under time pressure and without immediate expert support. Missed acute coronary occlusion - occlusion myocardial infarction (OMI) - delays reperfusion, while false…
- Conditions
- Acute Coronary Syndromes, ST Elevation Myocardial Infarction, Non-ST Elevated Myocardial Infarction, Myocardial Infarction (MI)
- Trial name
- ECG-IA (NCT07810686)
- Testing
- Smartphone large language model assistance (GPT-4o, version-locked)
- Where
- Switzerland
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital Care
Acute Coronary Syndromes, STEMI
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
This is a prospective, open-label, multicenter, randomized, phase IV clinical trial designed to evaluate the safety and efficacy of early aspirin discontinuation followed by potent P2Y12 inhibitor monotherapy after intravascular…
- Conditions
- Acute Coronary Syndromes, STEMI, NSTEMI, Unstable Angina
- Trial name
- SAPT-ACS (NCT07684742)
- Testing
- Early P2Y12 Inhibitor Monotherapy, Standard Dual Antiplatelet Therapy
- Where
- South Korea
- Volunteers
- 1,900 people
- Sponsor
- Gyeongsang National University Hospital
STEMI, Cardiogenic Shock
Circulating microRNAs in Patients With STEMI Complicated With Cardiogenic Shock
The aim of the study is knowing the prognostic value of circulating miRNAs in patients admitted to our hospital with STEMI complicated with cardiogenic shock.
- Conditions
- STEMI, Cardiogenic Shock, Acute Coronary Syndrome, microRNA
- Trial name
- NCT02691286
- Where
- Spain
- Volunteers
- 142 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Myocardial Infarction
Safety of TG100-115 for Heart Attack Treated With Angioplasty
TG100-115 is able to reduce the size of heart attacks in pre-clinical models. The hypothesis of this study is that TG100-115 can be given safely to patients who suffer a heart attack and undergo angioplasty to restore blood flow.
- Trial name
- NCT00103350
- Testing
- TG100-115
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- TargeGen
Coronary Heart Disease
Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction
The investigators evaluate the effects of intracoronary and intravenous administration of nicorandil on cardiac sympathetic nerve activity and distribution in patients with acute myocardial infarction undergoing primary…
- Trial name
- NCT04826497
- Testing
- nicorandil
- Volunteers
- 80 people
- Sponsor
- Xuzhou Central Hospital
Cardiovascular Diseases
Effects of Ticagrelor on No-reflow in Patients With Acute ST-segment Elevation Myocardial Infarction
The 'no-reflow' phenomenon after a percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) is a strong predictor of both short- and long-term mortality.
- Trial name
- NCT02798874
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Chinese PLA General Hospital
STEMI, Oxidative Stress
Correlations Between Oxidative Stress Biomarkers, h-FABP and Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Undergoing Primary PCI
The investigators intend to evaluate Oxidative Stress biomarkers through a. Catalase Activity Assay; b. Lipid Peroxidation Assay; c. SOD Assay; d. Total Antioxidant Capacity Assay; e.
- Conditions
- STEMI, Oxidative Stress, Oxidative Stress Induction, Primary PCI
- Trial name
- OxiSTEMIhFABP (NCT04034940)
- Testing
- Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients
- Where
- Romania
- Volunteers
- 200 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline